Acute Myeloid Leukemia

AML: Somatic Mutation Clearance May Be Prognostic for Survival

AML: Somatic Mutation Clearance May Be Prognostic for Survival

By

Researchers determined 3 levels of somatic mutation clearance based on VAF of residual mutations at CR.

Measurable Residual Disease After Induction May Predict Outcomes in Acute Myeloid Leukemia

Measurable Residual Disease After Induction May Predict Outcomes in Acute Myeloid Leukemia

By

Findings from previous studies suggests that multiparameter flow cytometric minimal residual disease may be used to predict outcomes in acute myeloid leukemia.

Sorafenib May Improve Outcomes in Patients With FLT3-ITD AML Receiving allo-HSCT

Sorafenib May Improve Outcomes in Patients With FLT3-ITD AML Receiving allo-HSCT

By

The most frequently observed adverse events among patients treated with sorafenib were cytopenias and skin rashes.

Romiplostim May Not Increase Acute Myeloid Leukemia Risk

Romiplostim May Not Increase Acute Myeloid Leukemia Risk

By

Previous studies showed that romiplostim for thrombocytopenia in MDS improved hematologic outcomes but may increase the risk of AML.

Radioactive Iodine Increases Risk of AML, CML in Patients With Thyroid Cancer

Radioactive Iodine Increases Risk of AML, CML in Patients With Thyroid Cancer

By

The risk of AML decreased after 2 years, returning to baseline within 6 years of WDTC diagnosis, but the risk of CML remained elevated for up to 10 years.

High-dose Cytarabine Significantly Improves Disease-free Survival in Adult AML

High-dose Cytarabine Significantly Improves Disease-free Survival in Adult AML

By

Researchers randomly assigned 597 patients with newly diagnosed AML to receive intermediate- or conventional-dose cytarabine plus homoharringtonine and daunorubicin.

Long-term Effects of Midostaurin Maintenance Are Unknown in <i>FLT3</i>-mutated AML

Long-term Effects of Midostaurin Maintenance Are Unknown in FLT3-mutated AML

By

At the end of maintenance, 57% and 64% of patients remained in the midostaurin arm or the placebo arm, respectively. There were 16 relapse events after maintenance in the midostaurin arm and 7 relapses and 2 deaths in the placebo arm.

Acute Leukemia: Highlights from ASH 2017

Acute Leukemia: Highlights from ASH 2017

Elias Jabbour, MD, discusses the latest developments in the treatment of acute and chronic leukemia from the ASH 2017 meeting.

Unrelated HSCT, UCBT May Yield Similar Survival Outcomes in Acute Leukemia

Unrelated HSCT, UCBT May Yield Similar Survival Outcomes in Acute Leukemia

By

For a meta-analysis, researchers evaluated outcomes data from 9 studies consisting of 6762 patients with an acute leukemia to determine whether HSCT is superior to UCBT.

FDA Grants Gilteritinib Fast Track Designation for FLT3-positive AML

FDA Grants Gilteritinib Fast Track Designation for FLT3-positive AML

By

Gilteritinib inhibits the FLT3 mutations observed in up to one-third of patients with AML, FLT3 internal tandem duplication, and the FLT3 tyrosine kinase domain.

Cabozantinib May Be Effective for Acute Myeloid Leukemia

Cabozantinib May Be Effective for Acute Myeloid Leukemia

By

Standard cytotoxic chemotherapy remains the standard treatment for AML, though a large proportion of patients relapse and/or develop resistance to conventional therapy, indicating a need for new treatments.

Novel Therapy May Overcome Chemotherapy Resistance in AML

Novel Therapy May Overcome Chemotherapy Resistance in AML

By

Researchers analyzed human AML samples to determine potential selective targets in leukemia stem cells, the source of resistance to standard chemotherapy.

Composite Complete Response Improved Guadecitabine Acute Myeloid Leukemia

Composite Complete Response Improved Guadecitabine Acute Myeloid Leukemia

By

Guadecitabine, a next-generation hypomethylating agent, has been shown to have a longer half-life and to prolong periods of exposure more than its predecessors.

Enasidenib: Well-tolerated and May Provide Benefit in R/R AML

Enasidenib: Well-tolerated and May Provide Benefit in R/R AML

By

Among patients with R/R disease, 19.3% achieved complete remission (CR) and had a median overall survival of 19.7 months.

FDA Approves Daunorubicin-Cytarabine Combination for AML Subtypes

FDA Approves Daunorubicin-Cytarabine Combination for AML Subtypes

By

Approval was based on data from a randomized phase 3 trial in which researchers compared the efficacy of the daunorubicin-cytarabine combination with that of a standard regimen.

FDA Approves Enasidenib for Relapsed/Refractory Acute Myeloid Leukemia

FDA Approves Enasidenib for Relapsed/Refractory Acute Myeloid Leukemia

By

The US Food and Drug Administration approved enasidenib for the treatment of adult patients with relapsed or refractory AML with an IDH2 mutation.

Gilteritinib Granted Orphan Drug Status for Acute Myeloid Leukemia

Gilteritinib Granted Orphan Drug Status for Acute Myeloid Leukemia

By

The US Food and Drug Administration granted orphan drug designation to gilteritinib for the treatment of AML.

Midostaurin Plus Chemotherapy Prolongs Survival in AML With FTL3 Mutation

Midostaurin Plus Chemotherapy Prolongs Survival in AML With FTL3 Mutation

By

Adding midostaurin — a multi-targeted kinase inhibitor — to chemotherapy prolongs overall survival (OS) among patients with newly diagnosed AML and an FLT3 mutation.

Phase 3 Vadastuximab Talirine Trials Halted Due to Deaths

Phase 3 Vadastuximab Talirine Trials Halted Due to Deaths

By

The data showed a higher rate of death, including fatal infections, in the vadastuximab talirine arm compared with the chemotherapy-only arm.

FDA Approves Midostaurin for Acute Myeloid Leukemia

FDA Approves Midostaurin for Acute Myeloid Leukemia

By

The FDA approved midostaurin for patients with newly diagnosed, FLT3 mutation-positive acute myeloid leukemia.

Advances in Non-precision Therapies Improve Outcomes in AML

Advances in Non-precision Therapies Improve Outcomes in AML

By

Study results support development of therapeutics that are targeted and based on individual genetic variants and would generalize across patient-groups in AML.

FDA Grants Priority Review to Midostaurin for Newly Diagnosed AML

FDA Grants Priority Review to Midostaurin for Newly Diagnosed AML

By

The FDA has granted Priority Review to the NDA for midostaurin (PKC412) for the treatment of adults with acute myeloid leukemia (AML).

"Beat AML" Master Trial Aims To Be Leader in Precision Medicine

"Beat AML" Master Trial Aims To Be Leader in Precision Medicine

By

This collaborative trial will test several new drugs in the clinical setting at major research institutions.

Norethandrolone With Maintenance Therapy Improves Survival in Elderly Patients With AML

Norethandrolone With Maintenance Therapy Improves Survival in Elderly Patients With AML

By

Maintenance therapy with norethandrolone improves survival of elderly patients with acute myeloid leukemia (AML) without increasing toxicity.

Age and Acute Myeloid Leukemia: A Review of Current Literature

Age and Acute Myeloid Leukemia: A Review of Current Literature

By

Dr Isabel Cunningham reviews and highlights important, recently published articles with recommendations for treating elderly patients with acute myeloid leukemia (AML).

Venetoclax Monotherapy Active in Acute Myelogenous Leukemia

Venetoclax Monotherapy Active in Acute Myelogenous Leukemia

In patients with acute myelogenous leukemia, the highly selective, oral small-molecule B-cell leukemia/lymphoma-2 (BCL2) inhibitor venetoclax is active.

Pracinostat Granted Breakthrough Therapy Designation for AML in Elderly Patients

Pracinostat Granted Breakthrough Therapy Designation for AML in Elderly Patients

By

The FDA granted Breakthrough Therapy Designation to pracinostat in combination with azacitidine for the treatment of acute myeloid leukemia (AML).

Vyxeos Improves Survival in Patients With High-risk AML

Vyxeos Improves Survival in Patients With High-risk AML

By

Vyxeos (CPX-351) statistically significantly improved overall survival as compared with the cytarabine and daunorubicin 7+3 regimen.

Midostaurin Receives Breakthrough Therapy Designation for AML

Midostaurin Receives Breakthrough Therapy Designation for AML

By

The FDA has granted Breakthrough Therapy Designation to midostaurin (PKC412) for acute myeloid leukemia (AML).

Gemtuzumab Ozogamicin May Improve Overall Survival in Acute Myeloid Leukemia

Gemtuzumab Ozogamicin May Improve Overall Survival in Acute Myeloid Leukemia

By

First-line monotherapy with low-dose gemtuzumab ozogamicin appeared to be superior in older patients with acute myeloid leukemia.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs